Bayer has inked an agreement with Attralus to acquire two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis.
The agents include AT-01 (a pan-amyloid binding peptide [PAR] labeled with iodine-124 [I-124] evuzamitide) for PET imaging and AT-05 (PAR-peptide labeled with technetium-99m) for SPECT imaging. AT-01 is in phase III clinical development, and AT-05 is in phase I.
AT-01 is the first of its kind with U.S. Food and Drug Administration (FDA) breakthrough therapy designation for cardiac amyloidosis and also carries orphan drug designation in both the U.S. and the EU, according to Bayer.
"The development of these tracers has the potential to address the urgent need for earlier and accurate diagnosis of systemic and specifically cardiac amyloidosis, a rarely diagnosed and often fatal heart disease that affects an estimated 400,000 people globally," the company said.
